Susquehanna International Group’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $99.2M | Sell |
299,700
-224,200
| -43% | -$76.3M | 0.01% | 836 |
|
|
2025
Q4 | $208M | Sell |
523,900
-277,300
| -35% | -$123M | 0.02% | 518 |
|
|
2025
Q3 | $365M | Buy |
801,200
+598,400
| +295% | +$244M | 0.04% | 347 |
|
|
2025
Q2 | $66.1M | Sell |
202,800
-51,600
| -20% | -$14.3M | 0.01% | 985 |
|
|
2025
Q1 | $68.7M | Buy |
254,400
+60,300
| +31% | +$15.5M | 0.01% | 844 |
|
|
2024
Q4 | $45.7M | Sell |
194,100
-168,600
| -46% | -$44.3M | 0.01% | 1196 |
|
|
2024
Q3 | $99.8M | Sell |
362,700
-550,800
| -60% | -$143M | 0.02% | 652 |
|
|
2024
Q2 | $222M | Buy |
913,500
+122,600
| +16% | +$19.4M | 0.04% | 332 |
|
|
2024
Q1 | $118M | Buy |
790,900
+352,100
| +80% | +$58.7M | 0.02% | 586 |
|
|
2023
Q4 | $84M | Buy |
438,800
+189,500
| +76% | +$32.3M | 0.02% | 757 |
|
|
2023
Q3 | $44.2M | Buy |
249,300
+79,900
| +47% | +$15.2M | 0.01% | 1096 |
|
|
2023
Q2 | $32.2M | Sell |
169,400
-17,100
| -9% | -$3.39M | 0.01% | 1305 |
|
|
2023
Q1 | $37.4M | Buy |
186,500
+16,400
| +10% | +$3.45M | 0.01% | 1143 |
|
|
2022
Q4 | $40.4M | Sell |
170,100
-150,900
| -47% | -$32.2M | 0.01% | 1010 |
|
|
2022
Q3 | $64.3M | Sell |
321,000
-230,900
| -42% | -$44M | 0.02% | 688 |
|
|
2022
Q2 | $80.5M | Buy |
551,900
+303,100
| +122% | +$43M | 0.02% | 604 |
|
|
2022
Q1 | $40.6M | Buy |
248,800
+80,800
| +48% | +$12.3M | 0.01% | 1131 |
|
|
2021
Q4 | $28.5M | Sell |
168,000
-3,200
| -2% | -$595K | ﹤0.01% | 1511 |
|
|
2021
Q3 | $32.3M | Buy |
171,200
+42,400
| +33% | +$7.95M | ﹤0.01% | 1521 |
|
|
2021
Q2 | $21.8M | Sell |
128,800
-11,700
| -8% | -$1.71M | ﹤0.01% | 1918 |
|
|
2021
Q1 | $19.8M | Buy |
140,500
+5,700
| +4% | +$858K | ﹤0.01% | 1883 |
|
|
2020
Q4 | $17.5M | Sell |
134,800
-152,400
| -53% | -$20.3M | ﹤0.01% | 1883 |
|
|
2020
Q3 | $41.8M | Sell |
287,200
-49,700
| -15% | -$7.06M | 0.01% | 962 |
|
|
2020
Q2 | $49.9M | Sell |
336,900
-33,500
| -9% | -$4.52M | 0.01% | 828 |
|
|
2020
Q1 | $40.3M | Buy |
370,400
+69,500
| +23% | +$8.02M | 0.01% | 751 |
|
|
2019
Q4 | $34.7M | Buy |
300,900
+106,500
| +55% | +$10.6M | 0.01% | 1028 |
|
|
2019
Q3 | $15.6M | Buy |
194,400
+94,000
| +94% | +$7.44M | 0.01% | 1534 |
|
|
2019
Q2 | $7.29M | Buy |
100,400
+2,800
| +3% | +$215K | ﹤0.01% | 2250 |
|
|
2019
Q1 | $9.12M | Sell |
97,600
-114,300
| -54% | -$9.56M | ﹤0.01% | 1828 |
|
|
2018
Q4 | $15.4M | Sell |
211,900
-194,000
| -48% | -$14.9M | 0.01% | 1247 |
|
|
2018
Q3 | $35.5M | Buy |
405,900
+221,800
| +120% | +$22.3M | 0.01% | 893 |
|
|
2018
Q2 | $18.1M | Sell |
184,100
-198,400
| -52% | -$19.7M | 0.01% | 1383 |
|
|
2018
Q1 | $45.6M | Sell |
382,500
-69,100
| -15% | -$8.91M | 0.02% | 706 |
|
|
2017
Q4 | $57.4M | Sell |
451,600
-662,500
| -59% | -$83.2M | 0.02% | 630 |
|
|
2017
Q3 | $131M | Buy |
1,114,100
+816,000
| +274% | +$69.7M | 0.05% | 303 |
|
|
2017
Q2 | $23.8M | Buy |
298,100
+26,300
| +10% | +$1.68M | 0.01% | 1027 |
|
|
2017
Q1 | $13.9M | Sell |
271,800
-48,900
| -15% | -$2.26M | 0.01% | 1346 |
|
|
2016
Q4 | $12M | Buy |
320,700
+9,700
| +3% | +$406K | 0.01% | 1398 |
|
|
2016
Q3 | $21.1M | Sell |
311,000
-9,500
| -3% | -$670K | 0.01% | 977 |
|
|
2016
Q2 | $17.8M | Buy |
320,500
+51,400
| +19% | +$3.24M | 0.01% | 1052 |
|
|
2016
Q1 | $16.9M | Buy |
269,100
+163,700
| +155% | +$10.9M | 0.01% | 1111 |
|
|
2015
Q4 | $9.92M | Sell |
105,400
-22,700
| -18% | -$2.1M | ﹤0.01% | 1761 |
|
|
2015
Q3 | $10.3M | Buy |
128,100
+21,000
| +20% | +$2.33M | ﹤0.01% | 1794 |
|
|
2015
Q2 | $12.8M | Sell |
107,100
-42,500
| -28% | -$5.08M | 0.01% | 1723 |
|
|
2015
Q1 | $15.6M | Buy |
149,600
+21,500
| +17% | +$2.18M | 0.01% | 1451 |
|
|
2014
Q4 | $12.4M | Sell |
128,100
-27,900
| -18% | -$2.58M | ﹤0.01% | 1782 |
|
|
2014
Q3 | $12.2M | Buy |
156,000
+22,800
| +17% | +$1.47M | ﹤0.01% | 1896 |
|
|
2014
Q2 | $8.41M | Buy |
133,200
+98,900
| +288% | +$5.88M | ﹤0.01% | 2322 |
|
|
2014
Q1 | $2.3M | Sell |
34,300
-9,300
| -21% | -$720K | ﹤0.01% | 4087 |
|
|
2013
Q4 | $2.81M | Sell |
43,600
-41,200
| -49% | -$2.46M | ﹤0.01% | 3748 |
|
|
2013
Q3 | $5.43M | Sell |
84,800
-4,500
| -5% | -$224K | ﹤0.01% | 2613 |
|
|
2013
Q2 | $2.77M | Buy |
+89,300
| New | +$2.38M | ﹤0.01% | 3384 |
|
Other funds holding ALNY
VPM
VCM
Susquehanna International Group's ALNY Position: Q1 2026 in Review
Susquehanna International Group reduced its Alnylam Pharmaceuticals (ALNY) stake by 9.2% in Q1 2026, selling an estimated $5.97M and leaving 174,268 shares worth $57.7M. The position accounts for 0.01% of the portfolio, ranked #1182.
Susquehanna International Group first reported a position in ALNY in Q3 2013 and has held it in 49 quarters since. The position peaked at $263M in Q3 2025. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.
- Susquehanna International Group held 174,268 shares of Alnylam Pharmaceuticals worth $57.7M as of Q1 2026.
- Susquehanna International Group sold 17,552 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $5.97M.
- Alnylam Pharmaceuticals made up 0.01% of Susquehanna International Group's portfolio in Q1 2026, its #1182 holding.
- Susquehanna International Group first reported a position in Alnylam Pharmaceuticals in Q3 2013 and has held it in 49 quarters since.
- Susquehanna International Group's Alnylam Pharmaceuticals position peaked at $263M in Q3 2025.
- 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.